Breaks Categories: News

WednesdaySep 06, 2017 10:45 am

NetworkNewsBreaks – Patriot One Technologies’ (TSX.V: PAT) (OTCQB: PTOTF) PATSCAN CMR™ Receives Industry Canada Certification

Patriot One Technologies, Inc. (TSX.V: PAT) (OTCQB: PTOTF) this morning announced that its award-winning PATSCAN CMR™ (Cognitive Microwave Radar) concealed weapons detection system has received Industry Canada (IC) certification for commercial use in Canada. Per the news release, initial deployments will be undertaken in collaboration with law enforcement and government agency personnel at several strategic locations. “We are gratified that a major regional police force has stepped forward to offer locations and personnel to assist our efforts in optimizing best practices for installation and operation,” Martin Cronin, CEO of Patriot One, stated in the news release. “We are also working…

Continue Reading

WednesdaySep 06, 2017 10:08 am

NetworkNewsBreaks – HighCom Global Security, Inc. (HCGS) Reports 116% YOY Increase in Q2 Revenues

Leading security solutions provider HighCom Global Security, Inc. (OTC: HCGS) this morning announced its financial results for the second quarter and first half of 2017. Among the highlights, the company reported $1.5 million in revenues for the three-month period, marking an increase of 116 percent from the second quarter of 2016. Likewise, HighCom Global recorded $2.6 million in revenues for the first half of 2017, marking a 37.5 percent increase from the comparable period of 2016. “We have consistently grown our revenues year-over-year, driven by increased consumer demand and our ability to meet corporate goals,” Craig Campbell, CEO of HighCom…

Continue Reading

WednesdaySep 06, 2017 9:39 am

NetworkNewsBreaks – SinglePoint, Inc. (SING) Announces Acquisition of Dr. FeelGood

Specialized holding company SinglePoint, Inc. (OTC: SING) this morning announced its acquisition of Dr. FeelGood, a profitable cannabis distribution company headquartered in Phoenix, Arizona. Per the terms of the agreement, SinglePoint will acquire a 51 percent stake in Dr. FeelGood in exchange for cash and stock, allowing SinglePoint to recognize all of the company’s revenue and effectively strengthening its revenue-by-acquisition strategy. “We are very excited for the success of this acquisition,” Greg Lambrecht, CEO of SinglePoint, stated in the news release. “The acquisition of Dr. FeelGood is the third acquisition of the year. SinglePoint's revenue has dramatically increased, which through…

Continue Reading

TuesdaySep 05, 2017 12:06 pm

NetworkNewsBreaks – Easton Pharmaceuticals, Inc. (EAPH) Marks C$1M Paid toward Alliance Group Partnership Agreement

Easton Pharmaceuticals (OTC: EAPH) this morning said it has advanced C$1 million in payments to Alliance Group pursuant to its previously announced closing agreement with Canada-based 124123 Ontario Inc. (O/A - Alliance Group). In turn, Alliance has executed C$8 million aggregate toward the LOI contract on its 90 acres of zoned industrial land. Easton has now paid a total of C$1 million out of the C$1.3 million required to acquire a 50% stake in 45 acres of agriculturally zoned land north of Toronto, Ontario, Canada, as well as a business to cultivate, produce and facilitate the sale of its production…

Continue Reading

TuesdaySep 05, 2017 12:03 pm

NetworkNewsBreaks – FuelCell Energy, Inc. (NASDAQ: FCEL) Secures 20 Megawatt Fuel Cell Project with Korea Southern Power Company

FuelCell Energy (NASDAQ: FCEL) this morning said it has secured a 20 megawatt fuel cell project with Korea Southern Power Company (KOSPO). The company intends to utilize the SureSource 3000™ power plant to cleanly produce electricity and thermal energy to support a district heating system. FuelCell expects to operate and maintain the installation under a 20-year service agreement. The company intends for the facility to be operational in 2018. “Our multi megawatt, scalable easy-to-site clean energy solutions are well-suited for utility-scale applications such as this project,” FuelCell Energy president and CEO Chip Bottone stated in the news release. Following this…

Continue Reading

TuesdaySep 05, 2017 12:01 pm

NetworkNewsBreaks – Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) Reports Positive Top Line Phase 2 Data of INOpulse® to Treat PH-COPD

Bellerophon Therapeutics (NASDAQ: BLPH) this morning reported positive top line data from its phase 2 clinical trial evaluating INOpulse® in patients with Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease (PH-COPD). The phase 2 study was designed to measure the acute effect of pulsed inhaled nitric oxide (iNO) on targeted vasodilation, as well as the chronic effect (4 weeks) of iNO on hemodynamics and exercise capacity. The acute effect results show statistically significant increases in blood vessel volume on iNO compared to baseline. Additionally, the chronic results demonstrated statistically significant and clinically meaningful increases in six-minute walking distance compared to…

Continue Reading

TuesdaySep 05, 2017 9:12 am

NetworkNewsBreaks – Global Payout, Inc. (GOHE) Looks to Achieve Fully Reporting Status within 60 Days

Payment solutions company Global Payout, Inc. (OTC: GOHE) this morning announced that it is currently in the process of completing its financial audit in preparation for the filing of Form 10-K, which the company expects will be completed within the next 60 days. “We are very pleased to have kicked-off the very important process of completing our audit and are optimistic in our ability to complete it within the next 60 days so that we enter a fully reporting status,” James Hancock, CEO of Global Payout, stated in the news release. “By becoming fully reporting, we are increasing our transparency…

Continue Reading

ThursdayAug 31, 2017 12:31 pm

NetworkNewsBreaks – Dextera Surgical, Inc.’s (NASDAQ: DXTR) MicroCutter 5/80™ Receives Expanded Indication Approval by FDA; Shares Higher

Dextera Surgical (NASDAQ: DXTR) shares are up 15% this morning after the company said it has received approval from the U.S. Food and Drug Administration (FDA) to use its MicroCutter 5/80 Stapler and MicroCutter 30 White and Curved Tip White Reloads in combination with open solid organ parenchymal dissection techniques, including such organs as the liver, kidney, pancreas and spleen. “This expanded indication represents an additional 44,000 procedures in the United States annually, and we look forward to bringing the MicroCutter 5/80 to surgeons for these applications,” Dextera Surgical president and CEO Julian Nikolchev stated in the news release. To…

Continue Reading

ThursdayAug 31, 2017 12:29 pm

NetworkNewsBreaks – Apricus Biosciences, Inc.’s (NASDAQ: APRI) Vitaros™ Class 2 NDA Resubmission Acknowledged by FDA; PDUFA Goal Date Set

Apricus Biosciences (NASDAQ: APRI) this morning said that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of its recently resubmitted New Drug Application (NDA) for Vitaros™ and considers it a complete, class 2 response to Apricus’ 2008 action letter. Additionally, the PDUFA (Prescription Drug User Fee Act) goal date for conclusion of the FDA’s review is set for the standard review period for NDA resubmissions of six months, falling on February 17, 2018. “The FDA has determined that the resubmission is a complete, class 2 response to our 2008 action letter.  Importantly, we believe that Vitaros, if approved, will…

Continue Reading

ThursdayAug 31, 2017 12:27 pm

NetworkNewsBreaks – SteadyMed (NASDAQ: STDY) Shares Plunge on Refusal to File Letter from FDA for Trevyent® NDA

SteadyMed (NASDAQ: STDY) shares are down 35% this morning after the company said it has received a refusal to file letter from the U.S. Food and Drug Administration (FDA) related to its New Drug Application (NDA) for Trevyent®. The Trevyent NDA was submitted in June 2017 for the treatment of Pulmonary Arterial Hypertension (PAH). Upon preliminary review of the NDA, the FDA determined that it was not adequately complete to permit a substantive review. The FDA has requested more details regarding certain device specifications and performance testing. The FDA also requested further design verification and validation testing on the final,…

Continue Reading